전립선 비대증 치료제 세계 시장 규모는 2024년 125억 달러에 달했습니다. IMARC Group은 이 시장이 2033년까지 185억 달러에 달하고, 2025-2033년 4.4%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측했습니다. 현재 북미가 시장을 독점하고 있으며, 2024년에는 34.8% 이상의 큰 점유율을 차지할 것으로 예측됩니다. 이 시장을 주도하는 요인으로는 고령 남성의 전립선 비대증 유병률 증가, 최소침습 수술의 발전, 약물 제제의 개선 등이 있습니다. 레이저 치료와 병용 치료의 기술 혁신은 환자의 치료 성적을 더욱 향상시켜 전립선 비대증 치료 시장 점유율을 높이고 있습니다.
전립선비대증(BPH) 치료 시장의 주요 촉진요인은 고령화 남성 인구의 BPH 유병률 증가, 비뇨기과 건강에 대한 인식 증가, 저침습적 치료법의 발전 등입니다. BPH가 배뇨 증상과 합병증 등 삶의 질에 미치는 영향 때문에 효과적인 치료법에 대한 수요가 증가하고 있습니다. 또한, 레이저 요법을 포함한 개발로 인해 약물의 처방과 조합이 개선되어 의료 접근성 증가 및 선진국의 유리한 상환 정책과 함께 시장 성장을 가속하고 있습니다. 예를 들어, 2024년 9월 Royal Surrey NHS Foundation Trust는 50세 이상 남성의 약 50%가 앓고 있는 양성 전립선비대증에 대한 에코레이저 치료를 도입했습니다. Prostate Project 자선단체의 지원을 받아 시행되는 이 최소침습 수술은 빠른 회복과 부작용을 최소화하고 환자의 삶의 질을 향상시키며 입원 기간을 단축시킵니다. 이러한 발전으로 전립선 비대증 치료 시장 전망은 밝습니다.
미국 전립선비대증(BPH) 치료제 시장의 주요 촉진요인은 남성 인구의 고령화에 따른 높은 BPH 유병률과 비뇨기과 건강에 대한 인식 증가입니다. 또한 레이저를 이용한 치료나 전립선 동맥 색전술과 같은 최소침습적 시술의 발전도 그 효율성과 빠른 회복 시간을 바탕으로 인기를 얻고 있습니다. 예를 들어, 2023년 7월, Adventist Health Portland는 물과 로봇의 정밀도를 이용한 전립선비대증(BPH)의 최소침습적 치료인 아쿠아브레이브 요법을 시작했습니다. 이 혁신적인 치료법은 전립선 비대증으로 고생하는 남성들에게 새로운 대안이 될 수 있습니다. 또한, 개선된 약물요법이나 병용요법도 이용할 수 있게 되어 치료 선택의 폭이 넓어지고 있습니다. 이는 미국의 중요한 전립선 비대증 치료 시장 동향 중 하나입니다.
저침습적 치료로의 전환
전립선비대증 치료에 있어서 최소침습적 수술이 많이 이용되고 있습니다. 미국 국립보건원(NIH)에 따르면, 중등도에서 중증의 전립선비대증 증상을 가진 남성의 약 30%가 어떤 형태로든 최소침습적 치료를 받고 있다고 합니다. 기술로는 레이저 치료, TUMT, TURP 등이 있습니다. 이들은 최소한의 회복시간으로 효과가 입증되어 환자와 의사 모두에게 인정받고 있습니다. 이러한 치료법은 주변 조직의 손상을 최소화하면서 치료가 이루어지기 때문에 출혈이나 감염 등의 합병증이 적습니다. 또한, 기존의 개복 수술에 비해 환자의 통증이 적고 정상적인 활동으로 빠르게 복귀할 수 있습니다. 이는 보다 덜 침습적인 외래 환자 중심의 서비스를 추구하는 헬스케어 분야의 일반적인 추세와 일치합니다. 홀뮴 레이저 핵출술이나 그린라이트 레이저 치료와 같은 기술의 성장은 시장 변화에 더욱 박차를 가하고 있으며, 현재 장기 입원이나 침습적 수술을 원하지 않는 환자들에게 대안을 제공합니다. 이러한 시술의 수용성 확대는 곧 전립선비대증 치료 시장 수요 증가로 이어질 것으로 보입니다.
첨단 약물 치료의 등장
새로운 약리요법의 등장으로 BPH 치료 환경이 크게 변화하고 있습니다. 새로운 약제군별 또는 병용요법은 부작용을 줄이면서 더 나은 증상 관리를 목표로 합니다. 미국 국립당뇨병-소화기-신장병 연구소(NIDDK)에 따르면, 51-60세 남성의 50%, 80세 이상 남성의 90%가 BPH를 앓고 있어 약리학적 치료의 필요성이 높아지고 있습니다. 알파차단제, 5알파 환원효소 억제제 등 전통적인 치료법이 계속 그 역할을 하고 있는 반면, 알파차단제나 5알파 환원효소 억제제 등 첨단 약물요법은 일반적인 치료법이지만 어지럼증, 성기능 장애 등 뚜렷한 부작용을 동반합니다. 아보다트나 시알리스와 같은 치료제의 특허가 만료됨에 따라 제네릭 의약품에 대한 기회가 확대되고, 저렴한 가격의 대체품이 제공되어 약물 치료 시장의 성장을 가속하고 있습니다. PDE5 억제제 및 새로운 이중 표적 치료제와 같은 약물 개발에 대한 노력이 증가하고 있으며, 증상 완화에 대한 보다 종합적인 접근 방식을 제공합니다. 이러한 첨단 약물은 전립선뿐만 아니라 BPH의 흔한 동반 질환인 발기부전까지 치료할 수 있습니다. 더 많은 치료법이 제공됨에 따라, 환자들은 자신의 건강 상태와 증상에 더 적합한 개별화된 증상 기반 치료 계획을 이용할 수 있게 되었습니다. 또한, 효능을 향상시키고 부작용을 최소화하기 위해 기존 의약품과 병용하는 추세도 나타나고 있습니다. 생물학적 제제 및 유전자 치료제의 임상시험 진입으로 BPH의 상황은 더욱 극적으로 변화할 것이며, 환자들에게 효과적인 장기 치료법이 제공될 것으로 보입니다.
노령인구 증가
세계 노인 인구는 BPH 치료 시장의 주요 성장 촉진요인입니다. 나이가 들수록 BPH의 발병률은 증가하며, 50세 이상의 남성에서 가장 많이 발생합니다. 1974년부터 2024년까지 전 세계 65세 인구 비율은 5.5%에서 10.3%로 거의 두 배로 증가합니다. 유엔의 인구통계학적 추정에 따르면, 2024년부터 2074년까지 이 수치는 두 배로 증가하여 20.7%를 보일 것으로 예측됩니다. 동시에 80세 이상 인구는 현재보다 3배 이상 증가할 것으로 예측됩니다. 선진국에서는 노인 인구가 크게 증가하여 전립선비대증 치료를 필요로 하는 인구가 크게 확대될 것으로 예측됩니다. 이러한 인구통계학적 변화는 효과적이면서도 합리적인 가격의 치료 개입을 요구하며, 의료 시스템에 더 많은 부담을 줄 것으로 보입니다. 전 세계 인구의 고령화로 인해 BPH 치료에 대한 수요가 증가하고 있으며, 제네릭 의약품은 환자 접근성 및 전체 치료 매출 증가를 위한 저비용 대안을 제공합니다. 고령의 남성은 고혈압, 당뇨병 등의 합병증이 발생하기 쉽습니다. 이러한 동반 질환은 BPH의 관리를 더욱 복잡하게 만들기 때문에 한 번에 여러 가지 건강상의 요구를 충족시키는 맞춤형 요법을 요구하는 원동력이 되고 있습니다. 노인은 어지럼증, 낙상 위험 증가 등 BPH 치료로 인한 부작용이 발생하기 쉽습니다. 고령화가 진행됨에 따라, 보다 안전한 치료를 통해 이러한 위험을 최소화하는 것이 헬스케어의 우선순위가 되고 있습니다. 따라서 제약회사와 헬스케어 기업들은 BPH의 증상을 치료하고 일반적으로 환자, 특히 노인의 삶의 질을 향상시킬 수 있는 의약품을 개발하기 위해 노력하고 있습니다. 고령화 사회는 외과적 치료뿐만 아니라 약리학적 치료에 대한 수요를 증가시킴으로써 앞으로도 계속 증가하여 시장에 영향을 미칠 것으로 예측됩니다.
The global benign prostatic hyperplasia treatment market size was valued at USD 12.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.5 Billion by 2033, exhibiting a CAGR of 4.4% during 2025-2033. North America currently dominates the market, holding a significant share of over 34.8% in 2024. The market is driven by the rising prevalence of BPH among aging men, advancements in minimally invasive procedures, and improved drug formulations. Innovations in laser therapies and combination treatments further enhance patient outcomes, increasing the benign prostatic hyperplasia treatment market share.
Key drivers in the benign prostatic hyperplasia (BPH) treatment market are the increasing prevalence of BPH among the aging male population, increasing awareness of urological health, and advances in minimally invasive treatment options. The demand for effective therapies is growing due to the impact of BPH on quality of life including urinary symptoms and complications. Innovations including laser therapy improved drug formulation and combinations also enhance growth in the market along with a rise in healthcare access as well as favorable reimbursement policies in developed regions. For instance, in September 2024, Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for benign prostate enlargement a condition affecting about 50% of men over 50. Funded by the Prostate Project charity, this minimally invasive procedure allows rapid recovery and minimal side effects improving patient quality of life and reducing hospital stays. These advancements are creating a positive benign prostatic hyperplasia treatment market outlook.
The key drivers of the United States benign prostatic hyperplasia (BPH) treatment market are a high prevalence of BPH among the aging male population and increased awareness of urological health. Advances in minimally invasive procedures such as laser-based therapies and prostatic artery embolization also gained popularity based on their efficiency and quicker recovery times. For instance, in July 2023, Adventist Health Portland launched Aquablation Therapy a minimally invasive treatment for benign prostatic hyperplasia (BPH) using water and robotic precision. This innovative procedure represents a new option for men dealing with enlarged prostate symptoms. There is also availability of improved medications and combination therapies which boost the range of treatment options. This further represents one of the key benign prostatic hyperplasia treatment market trends in the United States.
Shift Toward Minimally Invasive Procedures
Minimally invasive procedures are being increasingly used for the treatment of benign prostatic hyperplasia. According to the U.S. National Institutes of Health (NIH), an estimated 30% of men with moderate to severe BPH symptoms undergo some form of minimally invasive treatment. Techniques include laser therapy, TUMT, and TURP. These are well accepted by both patients and physicians because they have been proven effective with minimal recovery time. Such procedures ensure the treatment is targeted with minimal damage to the surrounding tissues and, therefore, fewer complications in the form of bleeding or infection. In addition, the patients face less pain and faster return to regular activities than the traditional open surgeries. This is in tune with the general trends in the healthcare sector toward less invasive outpatient-focused services. Growth of technologies like Holmium laser enucleation and GreenLight laser therapy further fueled the shifting market, to the extent that, nowadays, alternatives are offered to the patients who do not want to undergo long durations of hospitalization or an invasive surgery. The growing acceptance of these procedures will lead to increased benign prostatic hyperplasia treatment market demand over the time.
Emergence of Advanced Drug Therapies
The landscape of BPH treatment is undergoing a sea change with the emergence of new pharmacological therapies. New classes of drugs and combination therapies aim at better symptom management with fewer side effects. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 50% of men aged 51 to 60, and up to 90% of men over the age of 80, are affected by BPH, leading to a growing need for pharmacological treatment options. While traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors continue to play their role, advanced drug therapies, such as alpha-blockers and 5-ARIs, are common treatments but come with notable side effects like dizziness and sexual dysfunction. The expiration of patents for drugs like Avodart and Cialis has opened opportunities for generics, providing affordable alternatives and driving market growth in drug treatments. Efforts are increasing to develop drugs like PDE5 inhibitors and novel dual-target therapies offer a more holistic approach to symptom relief. These advanced drugs treat not only the prostate but also erectile dysfunction, a common comorbidity for BPH. With more treatments available, these patients can take advantage of an individualized, symptom-based plan that is better suited to his or her health conditions and symptoms. Yet another trend to be seen includes combining existing medicines to improve potency and minimize harmful side effects. The landscape for BPH is set to change even more dramatically with the entry of biologics and gene therapies into clinical trials, providing the patient with effective long-term treatment.
Rising Geriatric Population
The global geriatric population is a major growth driver for the BPH treatment market. As people age, the incidence of BPH increases, and the condition is most common in men over the age of 50. From 1974 to 2024, the global proportion of individuals aged 65 nearly doubled, rising from 5.5% to 10.3%. From 2024 to 2074, the figure is set to double once more, reaching 20.7%, as per United Nations demographic estimates. At the same time, the population of individuals aged 80 and older is expected to exceed three times its current size. The elderly population is expected to increase substantially in developed regions, thus significantly expanding the pool of people requiring treatment for BPH. This demographic change is likely to further stress healthcare systems by demanding effective yet affordable treatment interventions. An aging global population is fueling demand for BPH treatments, with generics offering lower-cost options that increase patient access and overall treatment sales. Older males are more predisposed to co-morbidities like hypertension and diabetes. Such comorbidities further complicate the management of BPH, thus resulting in a driving force for tailormade regimens that meet multiple health demands at one time. Older adults are more vulnerable to side effects from BPH treatments, including dizziness and an increased risk of falls. With an aging population, minimizing these risks through safer treatments is becoming a priority in healthcare. Pharmaceutical and healthcare companies, therefore, have been developing drugs that treat the symptoms of BPH and generally enhance the quality of life for patients, especially the elderly. The aging population is projected to continue increasing and influence the market by enhancing the demand for pharmacological as well as surgical treatment options.
Alpha-blockers account for the highest market benign prostatic hyperplasia treatment market share of the drug class category in BPH treatment. They are potent in offering symptomatic relief as quickly as possible. They are able to relax the muscles within the prostate and bladder neck to facilitate urine flow and reduce obstruction. Alpha-blockers are first-line drugs used for BPH due to their efficacy, availability and fewer side effects. Their ability to treat lower urinary tract symptoms without significantly altering prostate size makes them highly preferred by physicians. Increasing awareness, a growing aging male population and advancements in drug formulations further bolster the dominance of alpha-blockers in the BPH treatment market.
In 2024, North America accounted for the largest market share of over 34.8%. North America is the most significant market of BPH treatments mainly driven by the sophisticated healthcare infrastructure within the region and the high incidence of BPH among aging males along with better awareness about urological health. The United States is a notable contributor to the market due to its large population of geriatrics and the use of advanced medical treatments which include minimally invasive procedures as well as newer drug therapies. Favorable reimbursement policies along with cutting-edge technologies like robotic-assisted surgeries and laser therapies continue to support benign prostatic hyperplasia treatment market growth. The key pharmaceutical and medical device manufacturers located in the region also stimulate continuous innovation. The growing importance of early diagnosis and proactive management of BPH symptoms further enhance North America's position as a global leader in the BPH treatment market.
United States Benign Prostatic Hyperplasia Treatment Market
In 2024, the United States captured 85.00% of revenue in the North American market. The U.S. BPH market is increasing due to a growing aging male population and the rising awareness of treatment options. According to the American Urological Association, about 50% of men over 50 years old have BPH or an enlarged prostate. Prevalence of BPH rises with age and, among men aged 60 to 69 years, it reaches 70% and among those over 70 years, 80%. Growth drivers are major effective medical therapies like 5-alpha reductase inhibitors and alpha blockers along with increasing surgical procedure adoption. Market growth is further facilitated by a shift towards telemedicine and home-based treatments that ensure broader accessibility to care. This market is, therefore attracting more prominent players like AbbVie and Astellas into their portfolios by focusing on innovation and patient-centric approaches.
Europe Benign Prostatic Hyperplasia Treatment Market
The BPH market in the region is rapidly growing due to an aging population and the increasing prevalence of prostate enlargement. The European Association of Urology states that benign prostatic hyperplasia, or BPH, affects 50% of men over the age of 50, while the condition progresses with age and reaches 70% in the age group 60 to 69 and 80% above 70. The awareness about BPH symptoms and the high number of new diagnoses are main drivers for this market growth. In Germany, the UK, and France, among others, they are widely accepting advanced treatments with surgical minimally invasive approaches, drug therapies, and combination therapies where better management could be achieved for patients. Boehringer Ingelheim and Janssen, the two leading pharmaceutical giants, lead in innovating by introducing new drug formulations that meet unmet needs in BPH care. Additionally, telehealth solutions are picking up the pace in offering consultation and allowing for an early diagnosis that would be a driving factor in this European market growth.
Asia Pacific Benign Prostatic Hyperplasia Treatment Market
The Asia Pacific BPH market is growing rapidly because of the increasing awareness, aging male population, and improved access to healthcare. Asian Development Bank says, by 2050, one in four people in Asia and the Pacific will be over 60 years of age. Projections indicate that this demographic shift, where the population of older persons aged over 60 in the region is expected to triple from 2010 until 2050, will attain nearly 1.3 billion. This demographic shift will create a significant demand for BPH treatments as well, given the rising prevalence of BPH with age. According to an industry report, the market size for BPH was USD 1.8 billion in 2023 in this region, primarily driven by an escalating diagnosis rate and government initiatives to enhance the healthcare system in these countries. The main momentum-setters in this region are Japan, South Korea, and China, with the state-of-the-art advancements in BPH treatment technology, including robotic surgeries and novel pharmacological interventions. Herbal and traditional treatments are also gaining relevance more in the region, mainly in the Indian subcontinent.
Latin America Benign Prostatic Hyperplasia Treatment Market
Latin American BPH is experiencing a rising tide, mainly fueled by the rise in the population's aging demographic and the resultant increase in the need for effective treatment. According to the Pan American Health Organization (PAHO), 20% of men older than 50 years in this region suffer from BPH. In addition, there is a demand for BPH-related treatments within Brazil and Mexico. BPH progresses with age in a majority of Latin American male populations. Cancer of the prostate is the highest form of any cancer among male patients in Brazil and most cases, in fact, point to BPH. More recently, increased vigilance on symptomatic manifestations encourages men to search for treatments or even pharmaceutical-based and minimally invasive surgical treatments. Access to health care in Brazil and Mexico, for example, is expanding further, creating more room for market expansion. Local pharmaceutical firms and multinational players are also taking advantage of this trend to present a myriad of treatment options specific to the regional market.
Middle East and Africa Benign Prostatic Hyperplasia Treatment Market
The BPH market in the Middle East and Africa is set to grow based on the area's increasing aging population and growing attention to prostate care. According to the NIH, the prevalence rate of BPH in the Middle East ranges between 13.84% to 23.79%. In this regard, the variation was due to some demographic factors across the region in addition to differing access to care. As the male population aged above 50 continues to climb, BPH treatments remain in demand. Improving healthcare regimes in the form of better diagnosis rates are being recorded in Saudi Arabia and South Africa. Local players have scaled up their activities both on the medical and the surgical side, while international pharmaceutical majors have positioned themselves in the market. Increased attention on BPH management in both the public and private sectors is expected to spur major growth in the market over the next few years.
The benign prostatic hyperplasia (BPH) treatment market is highly competitive with numerous pharmaceutical and medical device companies offering a wide range of solutions from medications to minimally invasive procedures. Companies are focusing on innovation such as developing advanced drug formulations with improved efficacy and fewer side effects as well as refining minimally invasive techniques like laser therapies and robotic-assisted surgeries. The market is also seeing significant investment in clinical trials and the development of combination therapies to enhance treatment outcomes. Strategic partnerships, mergers and acquisitions are common enabling companies to expand their product portfolios and geographic reach.